Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

The human immunodeficiency virus type 1 (HIV-1) integrase mutations N155H and Q148R(H)(K) that reduce susceptibility to the integrase inhibitor raltegravir have been identified in patients failing treatment regimens containing raltegravir. Whether these resistance mutations occur individually or in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fransen, Signe, Gupta, Soumi, Danovich, Robert, Hazuda, Daria, Miller, Michael, Witmer, Marc, Petropoulos, Christos J., Huang, Wei
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology (ASM) 2009
Assuntos:
Vaccines and Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2772690/
https://ncbi.nlm.nih.gov/pubmed/19759152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01168-09
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares